Healio featured a JDD study on the use of tildrakizumab for plaque psoriasis. Jayme Heim, MSN, FNP-BC, and colleagues wrote, “Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study.” The study analyzed tildrakizumab, which is an anti-interleukin-23 p19 monoclonal antibody, when used for 28 weeks. Adults with moderate-to-severe plaque psoriasis received tildrakizumab 100 mg subcutaneously at the study onset and on weeks 4, 12 and 24. Of the 55 enrolled patients, 52 were assessed at week 28. Investigators found the mean PASI score decreased from 11.6 to 1.8. More than 55% of patients achieved PASI 90 response, and mean BSA decreased from 14.5% to 2.9%. Researchers also found serious adverse events to be infrequent. The authors noted that this study shows tildrakizumab treatment in the real world significantly improved clinical status and reduced psoriasis activity without any new safety concerns.
Healio also covered a JDD study on the use of artificial intelligence in diagnosing skin disease in patients with skin of color. Justine G. Schneider, of the research department of Moy-Fincher-Chipps Facial Plastics & Dermatology and The Ohio State University College of Medicine Dermatology Department, and colleagues wrote, “Diagnosis of Skin Disease in Moderately to Highly Pigmented Skin by Artificial Intelligence.” The study sought to determine the accuracy of AI in screening and triaging benign-neoplastic, malignant-neoplastic and non-neoplastic skin conditions in people with Fitzpatrick skin types IV-VI. Researchers used a set of 163 non-standardized clinical photographs that were diagnosed by a specialist. The custom-built AI software had an overall accuracy of 86.5% in diagnosing skin disease in these Fitzpatrick skin types. The authors noted that this is an improvement over reports that show a 44.3% clinician accuracy rate in diagnosing skin disease in darker skin tones. The authors wrote that AI could be used as a front-line screening tool to assist in triaging patients and providing a quicker path to an accurate diagnosis.
Dermatology Times featured a JDD study in the August issue’s Journal Digest. “Update on Hormonal Therapy in Hidradenitis Suppurativa” by Priyanka Karagaiah, MD, and colleagues from around the world reviewed research on finasteride, spironolactone, oral contraceptives and metformin. The authors wrote that current evidence is limited to retrospective case studies, small case series and case reports, and that the lack of randomized control trials makes conclusions about dosage, duration and possible adverse effects difficult to determine. Researchers recommend prescribers consider the age and sex of the patients and associated comorbidities, given the changes to the hormone profile and other treatment side effects.
